Interference of C-reactive protein with clotting times

Similar documents
Worldwide Report Coagulation Lot Exp 31 Oct 2018

Determination of APTT factor sensitivity the misguiding guideline

Insights on the Quality of Coagulation Testing

Warfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time

A Percent Correction Formula for Evaluation of Mixing Studies

MEASUREMENT OF ANTICOAGULANT EFFECTS OF NEW ORAL ANTICOAGULANTS PRACTICAL ASPECTS

Lupus Anticoagulant Testing Performance and Practices by North American Clinical Laboratories

Comparison of Three Methods for Measuring Factor VIII Levels in Plasma

Factor VIII Inhibitor Testing: Nijmegen Modifications, Experience and Recommendations

Lupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid

Mohammadreza Tabatabaei IBTO COAG LAB

Enrichment of Phospholipids from Biological Matrices with Zirconium Oxide-Modified Silica Sorbents

SUPPLEMENTAL MATERIAL. Number of patients 14

The Annexin V Apoptosis Assay

ECAT FOUNDATION REPORT

Comparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used in Coagulation Testing

Accepted: 12 November 2018

NANO 243/CENG 207 Course Use Only

ACTICLOT dpt REF 824. IVD C i 2 l. Dilute Prothrombin Time Test for the Determination of Lupus Anticoagulants (LA) (CPT Code No.

Suppl. Table 1: CV of pooled lipoprotein fractions analysed by ESI-MS/MS

THROMBOSIS PRODUCT HIGHLIGHTS

Clinical Study Synopsis

Generate Knowledge Lupus Anticoagulant Testing Made Simple

Effect of rivaroxaban on thrombin generation is modified by a P2Y 12 receptor blocker

HEMOSTASIS Quality Time saving Economy Practicability Quality assurance Precision

Instruments smart solutions & service IGZ Instruments AG Räffelstrasse 32 CH 8045 Zürich

Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital

Antiphospholipid Syndrome

Gladstone Institutes, University of California (UCSF), San Francisco, USA

Antiphospholipid antibodies in patients with venous thrombosis at Kenyatta National Hospital

Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University

CME/SAM. Influence of Coagulation and Anticoagulant Factors on Global Coagulation Assays in Healthy Adults

Presented by Marcelo Cardona, MT(ASCP) Johns Hopkins University

Diagnosis of hypercoagulability is by. Molecular markers

Evaluation of a rapid lateral flow immunoassay (STic Expert HIT) for the diagnosis of heparin-induced thrombocytopenia (HIT)

Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis

Mass Spectrometry based metabolomics

THROMBOPHILIA SCREENING

Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test.

Andexanet Alfa: Reversal agent for FXa Inhibitors

ALLOSTERIC REGULATION OF GPCR ACTIVITY BY PHOSPHOLIPIDS

The use of mass spectrometry in lipidomics. Outlines

Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions

Introduction to coagulation and laboratory tests

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

We are writing to inform you about an issue concerning your CoaguChek system and test strips. Please read this information carefully.

PS + MPs PS - MPs 37% 36% 64% 64%

The effects of ph on Type VII-NA Bovine Intestinal Mucosal Alkaline Phosphatase Activity

A new High Sensitive Functional Nephelometrical Assay for Assaying C- reactive protein in Serum Based on Phosphocholine Interaction Hani Alsaadi

antiphospholipid antibody binding to platelet membranes*

Instructions for Use. APO-AB Annexin V-Biotin Apoptosis Detection Kit 100 tests

Name and Intended Use

Annexin V-APC/7-AAD Apoptosis Kit

Electronic Supplementary Information

Beyond Clotting Time Clot Waveform Analysis (CWA)

DRG Anti-Phospholipid Screen IgG/IgM ELISA (EIA-3591) USA: RUO Revised 1 Aug rm (Vers. 5.1)

Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS

LOGO. Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University & Thai Society of Clinical Pathology

Use of PSI on CS instruments

Improved Distinction of Factor V Wild-Type and Factor V Leiden Using a Novel Prothrombin-Based Activated Protein C Resistance Assay

Chemical Surface Transformation 1

Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines

Kinetic assay of serum and urine for urea with use of urease and leucine dehydrogenase

URGENT FIELD SAFETY NOTICE IMMEDIATE ACTION REQUIRED

ator l English 1, 2, 3, 4, 5 ls 10 L

were isolated from the freshly drawn blood of healthy donors and ACS patients using the

LDL (Human) ELISA Kit

AlphaScreen TNFα Binding Assay Kit: A Homogeneous, Sensitive and High-Throughput Assay for Screening TNFα Receptors

Laboratory monitoring of oral anticoagulants. A/Prof. Lee Lai Heng Haematology Singapore General Hospital

Evaluation Report: Eurolyser CRP test (ST0100 and ST0102) on. CUBE analyser (CA0100)

1 Introduction Imprecision Within-run imprecision, results Day-to-day imprecision, results... 2

TECHNICAL SERIES. Lupus Anticoagulants: Basic Concepts and Laboratory Diagnosiss. ...Setting trends TULIP DIAGNOSTICS (P) LTD.

EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION

Coagulation and Transfusion Medicine

Sang Hyuk Park, 1,2 Seongsoo Jang, 3 Chan-Jeoung Park, 3 and Hyun-Sook Chi Introduction

Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation

Primary Exam Physiology lecture 5. Haemostasis

Vitamin K antagonist (VKA) therapy is routinely

Use of PSI on CS instruments

HbA1c (Human) ELISA Kit

Nori Rabbit IL-2 ELISA Kit DataSheet

This work is made available under the Creative Commons 4.0 License (CC BY4.0)

Human LDL ELISA Kit. Innovative Research, Inc.

PICT ANTICOAGULANT MONITORING 1. PEFAKIT PICT. Clotting Assay. PEFAKIT PiCT. PEFAKIT PICT Calibrators UFH. PEFAKIT PICT Controls UFH

Linköping University Post Print. Atrial fibrillation and platelet reactivity

New Anticoagulants: Laboratory Monitoring?? Dr Steve Kitchen Sheffield Haemostasis and Thrombosis centre UK

Cardiac Assessment Controls

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000

The PATH to better cardiac care starts here

assay Introduction Conclusions: The D-100 TM system proved to be a robust and reliable method for HbA 1c

See external label 96 tests HSV 2 IgA. Cat #

DIRECT ENZYMATIC HbA1c ASSAY

Multiple studies are available concerning the use of

Supplementary Table e-1. Flow cytometry reagents and staining combinations

SUPPLEMENTARY DATA. Materials and Methods

NOACS/DOACS*: COAGULATION TESTS

Human HBcAb IgM ELISA kit

Laboratory methods to detect antiphospholipid antibodies

Value-added reporting. X. Bossuyt

Supporting information

Transcription:

Clin Chem Lab Med 24; aop Letter to the Editor Katrien M.J. Devreese *, Charlotte J. Verfaillie, Frank De Bisschop and Joris R. Delanghe Interference of C-reactive protein with clotting times DOI.55/cclm-24-96 Received September 2, 24 ; accepted September 5, 24 Keywords: activated partial thromboplastin time; C-reactive protein; phospholipid; surface tension; thrombin generation. To the Editor, C-reactive protein (CRP) is an acute phase protein with a known affinity for phospholipids (PLs). Phosphatidylcholine (PC) is the principal CRP ligand, but CRP also interferes with other PL, e.g., phosphatidylethanolamine (PE) [ 3]. Recently, we illustrated that CRP interferes with activated partial thromboplastin time (aptt), prolonging clotting times (CT) proportionally with CRP concentration [4] and depending on the type of aptt reagent [4, 5]. PLs act as catalytic surfaces in clotting assays such as aptt, hence this phenomenon is most likely PL-dependent, with both concentration and type of PL taking part. To unravel the mechanism, we studied the influence of CRP on different aptt reagents. To work in PL-controlled conditions, we performed thrombin generation (TG) measurements by calibrated automated thrombinography (CAT ; Thrombinoscope, Maastricht, The Netherlands) [6]. We compared the results with the effect on thrombin time, a PL-independent clotting time (CT). Moreover, we compared the *Corresponding author: Katrien M.J. Devreese, Coagulation Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 85 (2P8), 9 Ghent, Belgium, Phone: + 32 9 332 65 67, Fax: + 32 9 332 49 85, E-mail: katrien.devreese@uzgent.be Charlotte J. Verfaillie: Coagulation Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Gent, Belgium Frank De Bisschop: Department of Inorganic and Physical Chemistry, Ghent University, Gent, Belgium Joris R. Delanghe: Chemistry Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Gent, Belgium effect of CRP with that of annexin V (AnV), a potent endothelial surface anticoagulant based on its ability to displace PL-dependent coagulation factors by binding to negatively charged PL, including phosphatidylserine (PS) and PE [, 7]. We attempted to visualize the binding of CRP to the PL surface by flow cytometry. Finally, we measured the PC content and the surface tension of the reagents because differences in interference of CRP may be determined by the accessibility of PL. Platelet-poor normal pooled plasma (NPP) was spiked with CRP or AnV and tested in duplicate on STAR-Evolution (Diagnostica Stago, Asni è res, France) with different aptt reagents and thrombin time. The reagents are listed in Table in Supplemental Material. Only limited information on the type and concentration of PL in these reagents was provided by the manufacturer. We used purified CRP prepared as described previously [8] to obtain a dilution series with a final CRP concentration of, 25, 5,, 5, 2, and 3 mg/l. The final concentration range of AnV (Sigma-Aldrich, St. Louis, MO, USA) (.9.36.72.4 μm) was based on current literature [7]. TG was triggered in platelet-poor plasma by tissue factor (TF, 5 pm) or silica (a /4 diluted aptt reagent, PTT-A; Diagnostica Stago) and PL (4 μ M). The CAT was performed as reported previously [6, 9]. Under these conditions, TG is PL-controlled, allowing to perform the test with different PLs separately: PE, PC, PS in purified linear structure (Sigma-Aldrich) and hexagonal PL (PE) of Staclot-LA (Diagnostica Stago) (HPE). Mixtures of PC and PS were used in a 7/3, 5/5, 3/7, /, and / proportion. The concentration of HPE in Staclot-LA reagent was not revealed by the manufacturer and was therefore used in different dilutions (/, /5, and /). To evaluate the prolongation of the lag time (LT) and the reduction of the peak height (PH), TG parameters were coupled in a PH/LT ratio [9]. Microparticles (MPs) were prepared by activating platelets with calcium ionophore (Sigma-Aldrich). Flow cytometric analysis of MP on FACSCanto II (Becton Dickinson, Erembodegem, Belgium) was performed with AnV

2 Devreese et al.: Interference of C-reactive protein with clotting times (ebioscience, San Diego, CA, USA) and CD4 (Analis/ Beckman Coulter, Suarl é e, Belgium) as described previously []. As competition between CRP and AnV for binding to PL was presumed, the strength of AnV staining of the MP in relation to the CRP concentration was studied. Furthermore, in an attempt to visualize MP-bound CRP, CRP was labeled with FITC (Sigma-Aldrich). In addition, FITC-labeled anti-crp (Abcam, Cambridge, UK) was used in parallel with anti-igg-fitc functioning as an isotypic control (Sigma-Aldrich). Surface tension of the reagents was measured using the Wilhelmy plate method []. All measurements were performed in duplicate. PC was measured using the LabAssay Phospholipid (Wako, Neuss, Germany), an enzymatic assay using N-ethyl-N-(2-hydroxy-3- sulfopropy)-3,5-domethoxyaniline [2]. Our spiking experiments confirmed that prolongation of aptt through CRP is dose- and reagent-dependent [4, 5]. CTs were prolonged with all aptt reagents (mean prolongation 64.%, range 33.2% 99.2%) with increasing CRP concentrations but not with thrombin time (see Table ). The two silica-based reagents frequently used in lupus anticoagulant (LAC) detection showed high sensitivity for CRP interference: we observed an aptt prolongation of more than 2% from 25 to 5 mg/l on for Staclot-LA PTT-LS (buffer) and PTT-LA, respectively. Staclot-LA PTT-LS with excess of HPE used as a confirmation test in LAC did not show a prolongation, thus matching with the mechanism of aptt prolongation by LAC due to competition of coagulation factors on negatively charged PL [4, 3, 4]. Cephascreen showed prolongation from 5 mg/l on and showed the most strongly prolonged aptt (up to 2% for 75 mg/l CRP). All other reagents showed prolongation from mg/l CRP on. As expected, thrombin time, a PL-independent coagulation test, was not influenced by CRP. A similar pattern of prolongation was observed for increasing concentrations of AnV ( Table 2 ), supporting the idea that prolongation of CT in PL-dependent assays by CRP is based on binding to negatively charged PL. To evaluate the influence on TG parameters, coefficients of variation (CVs, %) were calculated for NPP not spiked with CRP in all methodological conditions. Based on the maximal between-run CVs for PH/LT in test methods with PC, PS, and PE with silica and TF (28.5% and 7.6%, respectively) and in the test methods with HPE with silica and TF (55.6% and 22.2%, respectively), cutoffs for normalized PH/LT were set at.72, 2, 4, and.78, respectively. TG performed with PC, PS, PE, and variable PC/PS ratios (all 4 μ M final concentration), and both reaction triggers were not significantly decreased with increasing CRP concentrations ( 3 mg/l CRP) (see Figure A and B). TG performed with HPE was more Table Results of the CTs of NPP spiked with increasing CRP concentrations. Reagent. a (.)b 25. (38.4) b 5. (78.7) b. (65.2) b 5. (25.7) b 75. (32.2) b 2. (323.2) b PTT-A....5.6.7.6 C.K. Prest....5.7.7.6 Cephascreen...3.9 2. 2.2 2. Actin....6.7.9 Actin FS....6.8.9.9 Actin FSL....5 Pathromtin SL....5.6.6.6 SynthASil....3.3 APTT-SP....6.7.6.7 PTT-LA...5.5.6 Staclot LA (PTT-LS) With excess HPEc....... With buffer..3.5.5.5 Thrombin time...... a The sample with concentration was prepared by adding an equal volume of the native elution fluid to the NPP. Addition of a small volume of solution ( < % of total volume) was allowed without influence on CT by dilution effect. b Final CRP concentration measured in the spiked NPP through a particle enhanced immunoturbidimetric assay (CRPLX; Roche Diagnostics, Mannheim, Germany). c Test principle of Staclot-LA a LAC-sensitive aptt reagent (PTT-LS) is used, and aptt is performed twice, with addition of buffer (neutral) and with addition of excess of HPE. The experiments were performed with two different lots and all measurements were performed in duplicate. Only data for one lot of reagent are shown. The results are expressed as normalized ratios: CT of NPP spiked with CRP divided by the CT of the NPP without added CRP.

Devreese et al.: Interference of C-reactive protein with clotting times 3 Table 2 Results of the CTs of NPP spiked with increasing AnV concentrations. Reagent AnV, μm..9.36.72 4 PTT-A.....3.6 PTT-LA.9.9...7 3.4 SynthASil.9.9. 3.2 4. Staclot LA (PTT-LS) With excess HPE...... With buffer....6 2.3 The results are expressed as normalized ratios: CT of NPP spiked with AnV divided by the CT of the NPP without added AnV. sensitive to interference of CRP, at least at higher concentrations. A slight decrease (normalized ratio PH/LT.78) was observed from a CRP concentration of 5 mg/l on for TG triggered with TF and PE. TG with HPE diluted / showed a reduced PH/LT from 25 mg/l CRP on. CRP did not affect TG with higher dilution of HPE (/5 and /) (see Figure C and D). Corresponding with former findings, TG with HPE showed a decreased normalized PH/LT ratio starting from 24 mg/l CRP on, whereas for all other PL tested, TG showed no decrease in normalized PH/LT ratio at any CRP concentration [4]. These TG experiments suggest that not the type of PL but the conformation (linear vs. hexagonal structure) plays a role in interference by CRP, supporting the complex mechanism of CRP and PL interaction that can be influenced by the conformation of the PL [5]. Examples of TG curves are shown in Figure in the Supplemental Material. No competition of binding of AnV with CRP could be demonstrated by flow cytometric experiments. Binding of CRP to the MP could not be objectified as a reduced AnV-CD4-intensity (see Supplemental Material, Figure 2). AnV expression on MP did not decrease in the presence of increasing concentrations of CRP. Probably, AnV binds more strongly, compared with CRP, to the MP surface. By labeling CRP with FITC, no FITC staining of the MP was observed, nor could binding of CRP to the MP be demonstrated using FITC-labeled anti-crp (data not shown). Clotting assay reagents are mixtures of activators, PL, and non-specified additives. The large CRP molecule (5 kda) may be hampered for binding on the PL depending A TG with TF and PC, PS, PE 4 µm B TG with silica and PC, PS, PE 4 µm C PC/PS 7/3 PC/PS 5/5 PC/PS 3/7 PC/PS / PC/PS / PE 6 2.5 25 5 5 2 3 TG with TF and hexagonal PL Hexagonal PE / Hexagonal PE /5 Hexagonal PE / 6 2.5 25 5 5 2 3 D PC/PS 7/3 PC/PS 5/5 PC/PS 3/7 PC/PS / PC/PS / PE 6 2.5 25 5 5 2 3 TG with silica and hexagonal PL Hexagonal PE / Hexagonal PE /5 Hexagonal PE / 6 2.5 25 5 5 2 3 Figure Relation between normalized PH/LT and concentration of CRP. TG parameters were normalized by dividing the results for the samples spiked with CRP and those measured for the NPP not enriched with CRP.

4 Devreese et al.: Interference of C-reactive protein with clotting times A R=-.58 B R=.733 aptt clotting time prolongation, % 9 8 7 6 5 4 aptt clotting time prolongation, % 9 8 7 6 5 4 3 4 5 6 7 Surface tension, mn/m 3 5 5 2 25 Phosphatidyl choline, mg/l Figure 2 Correlation of aptt-ct prolongation with the surface tension (A) and phosphatidyl choline concentration (B). The percentage of aptt-ct prolongation is expressed as a ratio of aptt with the highest concentration of CRP to aptt without CRP. (A) A moderate correlation exists between the surface tension of the reagents and the aptt correlation. (B) A good correlation exists between the PL content of the reagent and the aptt prolongation. on the surface tension of the liquid. The surface tension for the aptt reagents ranged from 38.8 to 7.9 mn/m. A moderate correlation (Pearson correlation coefficient R =,58) was found between the surface tension and the extent of CT prolongation (see Figure 2 A): the higher the surface tension, the less the CRP-dependent prolongation of the CT, suggestive of a steric hindrance of the large CRP molecule toward binding to the PL in the reagent. We found a good correlation (R =.73) between the aptt prolongation and the PL content of the reagents (see Figure 2 B). The PC concentration ranged from 5 to 24 mg/dl. The high value measured in the CK Prest reagent (233 mg/l) was excluded. In conclusion, the in vitro interaction of CRP with PLdependent CTs is complex. Nonetheless, we demonstrated through the similar action of AnV compared with CRP that the mechanism of prolongation of the PL-dependent CT is based on binding to negatively charged PL. The interaction is not only influenced by the type of PL but rather by the conformation and the concentration of PL. Moreover, the variation in surface tension suggests that the overall constitution of the reagent plays a role in the CRP-dependent prolongation of the CT. Acknowledgments: The authors wish to thank M. Luypaert and E. Lecocq for their technical assistance. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Financial support: None declared. Employment or leadership: None declared. Honorarium: None declared. Competing interests: None. References. van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 25;25:77 22. 2. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2;38:89 97. 3. Mi LZ, Wang HW, Sui SF. Interaction of rabbit C-reactive protein with phospholipid monolayers studied by microfluorescence film balance with an externally applied electric field. Biophys J 997;73:446 5. 4. Schouwers SM, Delanghe JR, Devreese KM. Lupus anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res 2;25:2 4. 5. van Rossum AP, Vlasveld LT, van den Hoven LJ, de Wit CW, Castel A. False prolongation of the activated partial thromboplastin time (aptt) in inflammatory patients: interference of C-reactive protein. Br J Haematol 22;57:394 5. 6. Devreese K, Wijns W, Combes I, Van kerckhoven S, Hoylaerts MF. Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis. Thromb Haemost 27;98:6 3. 7. Rand JH, Wu XX, Lapinski R, van Heerde WL, Reutelingsperger CP, Chen PP, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 24;4:2783 9.

Devreese et al.: Interference of C-reactive protein with clotting times 5 8. Drieghe SA, Alsaadi H, Tugirimana PL, Delanghe JR. A new highsensitive nephelometric method for assaying serum C-reactive protein based on phosphocholine interaction. Clin Chem Lab Med 24;52:86 7. 9. Devreese K, Peerlinck K, Arnout J, Hoylaerts MF. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost 29;:85 96.. Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat- George F, et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2;8:257 4.. Ram, É. The interpretation of dynamic contact angles measured by the Wilhelmy plate method. J Colloid Interface Sci 997;85:245 5. 2. Takayama M, Itoh S, Nagasaki T, Tanimizu I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin Chim Acta 977;79:93 8. 3. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 29;7:737 4. 4. Devreese KM. Antiphospholipid antibody testing and standardization. Int J Lab Hematol 24;36:352 63. 5. Peng YN, Ho YL, Wu CY, Liu MY. Investigation of C-reactive protein binding to phosphatidyl choline by CZE and ESI-mass analysis. Electrophoresis 29;3:564 7.